BioXcel Therapeutics Inc

NASDAQ:BTAI   3:59:52 PM EDT
37.79
+0.28 (+0.75%)
Products

BioXcel Therapeutics Announces FDA Acceptance For Filing Of NDA For BXCL501

Published: 05/19/2021 11:30 GMT
BioXcel Therapeutics Inc (BTAI) - Bioxcel Therapeutics Announces FDA Acceptance for Filing of NDA for Bxcl501 for the Acute Treatment of Agitation Associated With Schizophrenia and Bipolar Disorders I and Ii.
Bioxcel Therapeutics Inc - FDA Sets PDUFA Action Date for January 5, 2022.
Bioxcel Therapeutics Inc - FDA is Not Planning to Hold an Advisory Committee Meeting to Discuss Application.